drugset / Trial / NCT07675174
Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
Non-randomizedSequentialOpen-labelPrevention
Summary
Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2030-07-01
- Completion
- 2032-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Subject | Sitagliptin | Small molecule | 400 mg | — |
| Subject | Sitagliptin | Small molecule | 600 mg | — |